Vazyme(SH:688105) Shang Hai Zheng Quan Bao·2025-09-02 19:43Core Viewpoint - The announcement details the share reduction plan by a major shareholder of Nanjing Novogene Bioinformatics Technology Co., Ltd., indicating a planned reduction of up to 11,932,036 shares, which is 3% of the total share capital, due to personal funding needs [3][4]. Shareholder Holding Situation - As of the announcement date, the shareholder Guoshou Chengda holds 30,957,960 shares, accounting for 7.78% of the company's total share capital, with these shares acquired prior to the company's initial public offering and released from restrictions on November 15, 2022 [2]. Reduction Plan Details - The reduction will occur through block trades and centralized bidding, with a maximum of 1% of total shares allowed to be sold in any 90-day period via centralized bidding and 2% via block trades. The reduction period is set from September 24, 2025, to December 23, 2025 [3][4]. - If there are changes in the company's capital structure, such as stock splits or capital increases, the number of shares subject to reduction will be adjusted accordingly [3]. Shareholder Commitment - The shareholder has committed to long-term holding of shares since the IPO and will notify the company in advance of any reduction plans, adhering to legal and regulatory requirements [7]. - The shareholder will comply with all relevant laws and regulations regarding shareholding and will publicly explain any failure to meet commitments [7]. Other Relevant Information - The reduction plan is consistent with previous commitments made by the shareholder, and it is confirmed that the major shareholder and executives have not reduced their holdings since the company's listing [5][8].